相关实验视频
Updated: Jun 27, 2025
09:10
Intestinal Epithelial Regeneration in Response to Ionizing Irradiation
Published on: July 27, 2022
2.2K
缺少IRAK1增强了放射治疗在抑制子宫癌发展方面的疗效
Wenjuan Chen1, Xingyun Xie2, Chengying Liu2
1Department of Radiotherapy, the First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, Fujian, PR China; Department of Radiotherapy, Gynecology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350014, Fujian, PR China.
Cellular signalling
|April 30, 2024
概括
互乐金-1受体关联激酶1 (IRAK1) 促进子宫癌的放射电阻. 减少IRAK1通过抑制NF-κB通路,增加癌细胞亡,提高放射治疗的疗效.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 放射治疗研究 放射治疗研究
背景情况:
- 介素-1受体相关激酶1 (IRAK1) 与癌症的发展和辐射抵抗有关.
- 对于IRAK1在宫癌放射电阻中的特定作用和机制尚不清楚.
研究的目的:
- 调查IRAK1在宫癌瘤发生和放射电阻中的作用.
- 阐明IRAK1影响放射治疗疗效的潜在机制.
主要方法:
- 在接受放射治疗的宫癌组织和细胞系 (HeLa,SiHa) 中IRAK1表达的分析.
- 在癌细胞中对IRAK1水平 (耗尽和过度表达) 的实验性操纵.
- 评估NF-κB通路的激活,细胞活力,细胞亡,细胞循环,迁移,入侵和殖民地形成.
- 使用异种移植小鼠模型进行体内研究.
主要成果:
- IRAK1表达与放射治疗疗效负相关.
- 电离辐射 (IR) 治疗降低了宫癌细胞中的IRAK1水平.
- IRAK1 枯竭增强了 IR 的抗癌作用,包括增加了细胞亡和细胞循环停止,部分是通过抑制 NF-κB 途径.
- 过度表达IRAK1产生了放射电阻,这种电阻被NF-κB抑制 (PDTC) 部分逆转.
- 在小鼠模型中,IRAK1缺乏改善了IR的抗增殖作用.
结论:
- 伊拉克1在调解宫癌对放射治疗的耐药性方面发挥着重要作用.
- 红外线治疗减少了IRAK1的表达,使得癌细胞更容易受到治疗的影响.
- 向IRAK1或NF-κB通路可能会改善宫癌的放射治疗结果.
相关概念视频
02:34Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
01:27Tumor Immunotherapy
520
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
520
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
160
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
160
02:38Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K